S&P 500   4,590.95 (+0.86%)
DOW   35,666.16 (+0.49%)
QQQ   383.74 (+0.98%)
AAPL   152.61 (+2.53%)
MSFT   323.73 (+0.17%)
FB   319.80 (+2.43%)
GOOGL   2,919.86 (-0.15%)
TSLA   1,070.03 (+3.10%)
AMZN   3,472.34 (+2.35%)
NVDA   248.15 (+1.49%)
BABA   169.91 (+0.40%)
NIO   40.55 (+3.15%)
CGC   13.05 (+2.11%)
GE   104.79 (+0.91%)
AMD   120.89 (-1.14%)
MU   69.44 (+1.76%)
T   25.62 (+2.23%)
F   16.95 (+9.28%)
ACB   6.94 (+1.46%)
DIS   170.11 (+0.33%)
PFE   43.17 (+0.47%)
BA   208.20 (+0.77%)
AMC   35.17 (+1.18%)
S&P 500   4,590.95 (+0.86%)
DOW   35,666.16 (+0.49%)
QQQ   383.74 (+0.98%)
AAPL   152.61 (+2.53%)
MSFT   323.73 (+0.17%)
FB   319.80 (+2.43%)
GOOGL   2,919.86 (-0.15%)
TSLA   1,070.03 (+3.10%)
AMZN   3,472.34 (+2.35%)
NVDA   248.15 (+1.49%)
BABA   169.91 (+0.40%)
NIO   40.55 (+3.15%)
CGC   13.05 (+2.11%)
GE   104.79 (+0.91%)
AMD   120.89 (-1.14%)
MU   69.44 (+1.76%)
T   25.62 (+2.23%)
F   16.95 (+9.28%)
ACB   6.94 (+1.46%)
DIS   170.11 (+0.33%)
PFE   43.17 (+0.47%)
BA   208.20 (+0.77%)
AMC   35.17 (+1.18%)
S&P 500   4,590.95 (+0.86%)
DOW   35,666.16 (+0.49%)
QQQ   383.74 (+0.98%)
AAPL   152.61 (+2.53%)
MSFT   323.73 (+0.17%)
FB   319.80 (+2.43%)
GOOGL   2,919.86 (-0.15%)
TSLA   1,070.03 (+3.10%)
AMZN   3,472.34 (+2.35%)
NVDA   248.15 (+1.49%)
BABA   169.91 (+0.40%)
NIO   40.55 (+3.15%)
CGC   13.05 (+2.11%)
GE   104.79 (+0.91%)
AMD   120.89 (-1.14%)
MU   69.44 (+1.76%)
T   25.62 (+2.23%)
F   16.95 (+9.28%)
ACB   6.94 (+1.46%)
DIS   170.11 (+0.33%)
PFE   43.17 (+0.47%)
BA   208.20 (+0.77%)
AMC   35.17 (+1.18%)
S&P 500   4,590.95 (+0.86%)
DOW   35,666.16 (+0.49%)
QQQ   383.74 (+0.98%)
AAPL   152.61 (+2.53%)
MSFT   323.73 (+0.17%)
FB   319.80 (+2.43%)
GOOGL   2,919.86 (-0.15%)
TSLA   1,070.03 (+3.10%)
AMZN   3,472.34 (+2.35%)
NVDA   248.15 (+1.49%)
BABA   169.91 (+0.40%)
NIO   40.55 (+3.15%)
CGC   13.05 (+2.11%)
GE   104.79 (+0.91%)
AMD   120.89 (-1.14%)
MU   69.44 (+1.76%)
T   25.62 (+2.23%)
F   16.95 (+9.28%)
ACB   6.94 (+1.46%)
DIS   170.11 (+0.33%)
PFE   43.17 (+0.47%)
BA   208.20 (+0.77%)
AMC   35.17 (+1.18%)
NASDAQ:TRVI

Trevi Therapeutics Stock Forecast, Price & News

$1.12
-0.06 (-5.08 %)
(As of 10/28/2021 01:18 PM ET)
Add
Compare
Today's Range
$1.12
$1.18
50-Day Range
$1.18
$2.10
52-Week Range
$1.10
$3.98
Volume
8,694 shs
Average Volume
1.04 million shs
Market Capitalization
$26.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.02
30 days | 90 days | 365 days | Advanced Chart
Receive TRVI News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Trevi Therapeutics logo

About Trevi Therapeutics

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVI
Employees
8
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.48 per share

Profitability

Net Income
$-32.76 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
15,146,000
Market Cap
$26.88 million
Next Earnings Date
11/11/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.12 out of 5 stars

Medical Sector

453rd out of 1,374 stocks

Pharmaceutical Preparations Industry

204th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions

Is Trevi Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Trevi Therapeutics stock.
View analyst ratings for Trevi Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Trevi Therapeutics?

Wall Street analysts have given Trevi Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trevi Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Trevi Therapeutics?

Trevi Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totaling 139,700 shares, an increase of 25.9% from the September 30th total of 111,000 shares. Based on an average daily trading volume, of 373,200 shares, the short-interest ratio is currently 0.4 days. Currently, 2.4% of the shares of the company are sold short.
View Trevi Therapeutics' Short Interest
.

When is Trevi Therapeutics' next earnings date?

Trevi Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Trevi Therapeutics
.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) posted its quarterly earnings data on Thursday, August, 12th. The company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.03.
View Trevi Therapeutics' earnings history
.

How has Trevi Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Trevi Therapeutics' stock was trading at $3.18 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRVI shares have decreased by 64.8% and is now trading at $1.12.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TRVI?

1 equities research analysts have issued 12 month price objectives for Trevi Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Trevi Therapeutics' share price to reach $10.00 in the next year. This suggests a possible upside of 792.9% from the stock's current price.
View analysts' price targets for Trevi Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Trevi Therapeutics' key executives?

Trevi Therapeutics' management team includes the following people:
  • Jennifer L. Good, President, Chief Executive Officer & Director
  • Lisa Delfini, Chief Financial Officer
  • Thomas R. Sciascia, Chief Medical Officer
  • Danine Summers, Vice President-Medical Affairs
  • William P. Forbes, Chief Development Officer

What other stocks do shareholders of Trevi Therapeutics own?

When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an IPO on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

How do I buy shares of Trevi Therapeutics?

Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $1.12.

How much money does Trevi Therapeutics make?

Trevi Therapeutics has a market capitalization of $26.88 million. The company earns $-32.76 million in net income (profit) each year or ($1.81) on an earnings per share basis.

How many employees does Trevi Therapeutics have?

Trevi Therapeutics employs 8 workers across the globe.

What is Trevi Therapeutics' official website?

The official website for Trevi Therapeutics is www.trevitherapeutics.com.

Where are Trevi Therapeutics' headquarters?

Trevi Therapeutics is headquartered at 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at (203) 304-2499 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.